Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience Corporation (TWST) and Centogene N.V. (CNTG) have partnered to develop custom assay kits targeting the diagnosis of rare diseases. This collaboration aims to enhance genetic testing accessibility for patients, ultimately improving understanding and treatment of rare conditions. Although no financial details were disclosed, the partnership seeks to utilize Centogene's extensive Bio/Databank and Twist's DNA synthesis technologies. The initiative is part of Centogene's goal to drive insights and potentially cure up to 100 rare diseases within the next decade.
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its product offerings with the launch of the Twist Alliance Pan-Cancer Methylation Panel, designed for extensive cancer research applications. This panel, developed in collaboration with the Regeneron Genetics Center, covers 31 cancer types, optimizing sequencing costs and analysis complexity. Validation of the panel shows its effectiveness in differentiating cancer from non-malignant tissues. Twist's Alliance Panels aim to enhance research capabilities by providing expert-designed, clinically validated tools.
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dennis Cho as senior vice president, general counsel, and chief ethics and compliance officer. With over 25 years of corporate legal experience in the biotech industry, Cho aims to support Twist’s growth across synthetic biology and genomics. Previously, he held significant roles at CytomX Therapeutics and Seattle Genetics. CEO Emily Leproust expressed confidence in Cho's expertise to guide the company’s strategic initiatives. Twist strives to revolutionize DNA synthesis and applications across various industries, including healthcare and agriculture.
Twist Bioscience Corporation (TWST) announced promising results for its antibody candidate TB202-3, showing potent binding to various SARS-CoV-2 variants, including the E484K, N501Y, and D614G mutations. Conducted by the Coronavirus Immunotherapy Consortium, the analysis demonstrated that TB202-3 completely obstructs the virus's binding to human ACE2, indicating its potential effectiveness against COVID-19. The company is also advancing a new antibody, TB339-031, targeting additional variants. These findings underscore the antibody's broad applicability amidst evolving viral strains.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with deepCDR, focused on advanced antibody discovery using deep learning algorithms. This partnership aims to enhance Twist's ability to generate large panels of fully human antibody sequences, utilizing new AI Hypermutated scFv libraries. The collaboration is expected to streamline preclinical development by reducing validation work. Twist's innovative silicon platform enables the manufacturing of high-quality synthetic DNA, which is crucial for various applications, including drug discovery and genomics.
Illumina Ventures has closed its second investment fund, raising
Twist Bioscience Corporation announces the availability of synthetic RNA reference controls for the latest SARS-CoV-2 variants, AY.1 and AY.2, enhancing the accuracy of diagnostic tests. The company now offers a total of 22 synthetic RNA controls targeting SARS-CoV-2 and 15 for respiratory viruses. This initiative demonstrates Twist's commitment to monitoring viral evolution and developing effective testing tools. The synthetic controls are used globally in various assays and are noted for their sequence verification and coverage of the full viral genome.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Twist Bioscience Corporation (NASDAQ:TWST) has entered a research collaboration with Boehringer Ingelheim to discover therapeutic antibodies using Twist's proprietary antibody libraries. This partnership enables the identification and optimization of potential antibody candidates across multiple targets. Twist will receive an upfront payment for each program and could earn up to $710 million in milestone payments related to clinical and regulatory success. The collaboration highlights Twist’s capabilities in antibody development aimed at personalized treatments.
Twist Bioscience Corporation (NASDAQ:TWST) announced a collaboration with Boehringer Ingelheim to utilize Twist's proprietary antibody libraries for discovering therapeutic antibodies. The agreement allows for a wide range of disease targets and grants Boehringer Ingelheim exclusive rights to develop any resulting antibodies. Twist will receive upfront payments for each program and could earn up to $710 million in milestone payments. Both companies aim to create new, personalized treatments for patients.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
